Patents.us
Patents/USRE050880

USRE050880No. USRE050880reissueGranted 5/5/2026
Patent USRE050880 — — Figure 1
Fig. 1 ·

Claims (59)

Claim 1 (Independent)

1 . An antibody or a fragment thereof that specifically binds to hOX40L and competes for binding to said hOX40L with the antibody 02D10 which comprises a heavy chain amino acid sequence of SEQ ID No:62 and a light chain amino acid sequence of SEQ ID No:64, the antibody or fragment thereof comprising a VH domain which comprises the HCDR3 sequence of SEQ ID NO:40 or 46.

Claim 15 (Independent)

15 . A composition comprising an antibody or a fragment thereof that specifically binds to hOX40L and competes for binding to said hOX40L with the antibody 02D10 which comprises a heavy chain amino acid sequence of SEQ ID No:62 and a light chain amino acid sequence of SEQ ID No:64, and a pharmaceutically acceptable excipient, diluent, or carrier; wherein the antibody or fragment thereof comprises a VH domain comprising the HCDR3 sequence of SEQ ID NO:40 or 46.

Claim 28 (Independent)

28. An antibody that specifically binds to hOX40L and comprises a VH domain comprising the HCDR1 sequence of SEQ ID NO:36 or 42, the HCDR2 sequence of SEQ ID NO: 38 or 44, and the HCDR3 sequence of SEQ ID NO:40 or 46, and a VL domain comprising the LCDR1 sequence of SEQ ID NO: 50 or 56, the LCDR2 sequence of Ala-Ala-Ser or 58, and the LCDR3 sequence of SEQ ID NO:54 or 60.

Claim 30 (Independent)

30. An antibody that specifically binds to hOX40L and comprises a VH domain comprising SEQ ID NO:34 and a VL domain comprising SEQ ID NO:48.

Claim 31 (Independent)

31. An antibody that specifically binds to hOX40L and comprises two copies of a heavy chain comprising SEQ ID NO:62 and two copies of a light chain comprising SEQ ID NO:64.

Claim 32 (Independent)

32. An antibody that specifically binds to hOX40L and consists of two copies of a heavy chain consisting of SEQ ID NO:62 and two copies of a light chain consisting of SEQ ID NO:64.

Claim 44 (Independent)

44. An antibody or a fragment thereof that specifically binds to hOX40L and competes for binding to said hOX40L with the antibody 02D10, which comprises a heavy chain amino acid sequence of SEQ ID NO:62 and a light chain amino acid sequence of SEQ ID NO:64, the antibody or fragment thereof comprising (i) a VH domain which comprises the HCDR1 sequence of SEQ ID NO:36 or 42, the HCDR2 sequence of SEQ ID NO:38 or 44, and the HCDR3 sequence of SEQ ID NO:40 or 46; and (ii) a VL domain that comprises the LCDR1 sequence of SEQ ID NO:50 or 56, the LCDR2 sequence of Ala-Ala-Ser or SEQ ID NO:58, and the LCDR3 sequence of SEQ ID NO:54 or 60.

Show 52 dependent claims
Claim 2 (depends on 1)

2 . The antibody or fragment thereof according to claim 1 , wherein the VH domain comprises the HCDR1 sequence of SEQ ID NO:36 or 42.

Claim 3 (depends on 1)

3 . The antibody or fragment thereof according to claim 1 , wherein the VH domain comprises the HCDR1 sequence of SEQ ID NO:36 or 42, and the VH domain comprises the HCDR2 sequence of SEQ ID NO:38 or 44.

Claim 4 (depends on 1)

4 . The antibody or fragment thereof according to claim 1 , wherein the VH domain comprises the HCDR1 sequence of SEQ ID NO:36 or 42, and the VH domain comprises the HCDR2 sequence of SEQ ID NO:38 or 44, and wherein the antibody or fragment thereof further comprises a VL domain which comprises the LCDR1 sequence of SEQ ID NO:54 or 60.

Claim 5 (depends on 1)

5 . The antibody or fragment thereof according to claim 1 , wherein the VH domain comprises the HCDR1 sequence of SEQ ID NO:36 or 42, and the VH domain comprises the HCDR2 sequence of SEQ ID NO:38 or 44, and wherein the antibody or fragment thereof further comprises a VL domain comprising the LCDR1 sequence of SEQ ID NO:54 or 60, and the VL domain comprising the LCDR2 sequence of SEQ ID NO:52 or 58.

Claim 6 (depends on 1)

6 . The antibody or fragment thereof according to claim 1 , wherein the VH domain comprises the HCDR1 sequence of SEQ ID NO:36 or 42, and the VH domain comprises the HCDR2 sequence of SEQ ID NO:38 or 44, and wherein the antibody or fragment thereof further comprises a VL domain comprising the LCDR1 sequence of SEQ ID NO:54 or 60, the VL domain comprising the LCDR2 sequence of SEQ ID NO:52 or 58, and the VL domain comprising the LCDR3 sequence of SEQ ID NO:54 or 60.

Claim 7 (depends on 6)

7 . The antibody or fragment thereof according to claim 6 , wherein the VH domain comprises the amino acid sequence of SEQ ID NO:34.

Claim 8 (depends on 6)

8 . The antibody or fragment thereof according to claim 6 comprising a first and a second copy of the VH domain.

Claim 9 (depends on 6)

9 . The antibody or fragment thereof according to claim 6 , wherein the VL domain comprises the amino acid sequence of SEQ ID NO:48.

Claim 10 (depends on 6)

10 . The antibody or fragment thereof according to claim 6 , wherein the VL domain comprises the amino acid sequence of SEQ ID NO:48 and the VH domain comprises the amino acid sequence of SEQ ID NO:34.

Claim 11 (depends on 6)

11 . The antibody or fragment thereof according to claim 6 comprising a first and a second copy of the VL domain.

Claim 12 (depends on 6)

12 . The antibody or fragment thereof according to claim 6 comprising a kappa light chain.

Claim 13 (depends on 6)

13 . The antibody or fragment thereof according to claim 6 comprising a constant region.

Claim 14 (depends on 10)

14 . The antibody or fragment thereof according to claim 10 comprising a IgG4-PE constant region of SEQ ID NO:128.

Claim 16 (depends on 15)

16 . The composition according to claim 15 , wherein the VL domain comprises the amino acid sequence of SEQ ID NO:48 and the VH domain comprises the amino acid sequence of SEQ ID NO:34.

Claim 17 (depends on 15)

17 . The composition according to claim 15 , further comprising another agent that is a therapeutic or prophylactic agent for graft versus host disease (GvHD) or transplant rejection.

Claim 18 (depends on 15)

18 . The composition according to claim 15 contained in a kit with a label or instructions for use to treat and/or prevent graft versus host disease (GvHD) or transplant rejection.

Claim 19 (depends on 18)

19 . The composition according to claim 18 , wherein the kit comprises a marketing authorisation number.

Claim 20 (depends on 18)

20 . The composition according to claim 18 , wherein the kit further comprises an IV or injection device that comprises the antibody or fragment thereof.

Claim 21 (depends on 6)

21 . A method of treating or preventing graft versus host disease (GvHD) or transplant rejection in a human in need thereof, the method comprising administering to said human a therapeutically effective amount of an antibody or fragment thereof as defined in claim 6 , wherein the graft versus host disease (GvHD) or transplant rejection is thereby treated or prevented.

Claim 22 (depends on 21)

22 . The method according to claim 21 , wherein the antibody or fragment thereof is administered prophylactically.

Claim 23 (depends on 21)

23 . The method according to claim 21 , wherein the antibody or fragment thereof is administered prophylactically and wherein the antibody or fragment thereof enables greater than 80% stem cell donor chimerism by day 12 in a Rhesus macaque model of haploidentical hematopoietic stem cell transplantation.

Claim 24 (depends on 21)

24 . The method according to claim 21 , wherein the antibody or fragment thereof is administered prophylactically and wherein the antibody or fragment thereof maintains a naïve population of CD4+ T cells of >20% of total CD4+ T cell population at day 12 in a Rhesus macaque model of haploidentical hematopoietic stem cell transplantation.

Claim 25 (depends on 21)

25 . The method according to claim 21 , wherein the antibody or fragment thereof is administered prophylactically and further comprising administering to the human a further therapeutic or preventative agent for graft versus host disease or transplant rejection.

Claim 26 (depends on 13)

26 . The antibody or fragment thereof according to claim 13 , wherein the constant region comprises an IgG4-PE constant region, wherein the IgG4-PE constant region comprises a Leu235Glu mutation and a Ser228Pro mutation relative to the wild-type IgG4 constant region.

Claim 27 (depends on 15)

27 . The composition of claim 15 , wherein the VH domain of the antibody or fragment thereof comprises the HCDR1 sequence of SEQ ID NO:36 or 42, and the HCDR2 sequence of SEQ ID NO:38 or 44, and wherein the antibody or fragment thereof comprises a VL domain which comprises the LCDR1 sequence of SEQ ID NO: 54 or 60 50 or 56 , the LCDR2 sequence of Ala-Ala-Ser or SEQ ID NO: 52 or 58, and a LCDR3 sequence of SEQ ID NO:54 or 60.

Claim 29 (depends on 28)

29. The antibody of claim 28 , further comprising a human heavy chain constant region and a human light chain constant region.

Claim 33 (depends on 15)

33. The composition of claim 15 , wherein the VH domain comprises an amino acid sequence comprising SEQ ID NO:36, SEQ ID NO:38, and SEQ ID NO:40; and the VL domain comprises an amino acid sequence comprising SEQ ID NO:50, Ala-Ala-Ser, and SEQ ID NO:54.

Claim 34 (depends on 15)

34. The composition of claim 15 , wherein the VH domain comprises an amino acid sequence comprising SEQ ID NO:42, SEQ ID NO:44, and SEQ ID NO:46; and the VL domain comprises an amino acid sequence comprising SEQ ID NO:56, SEQ ID NO:58, and SEQ ID NO:60.

Claim 35 (depends on 28)

35. The antibody of claim 28 , wherein the VH domain comprises an amino acid sequence comprising SEQ ID NO:36, SEQ ID NO:38, and SEQ ID NO:40; and the VL domain comprises an amino acid sequence comprising SEQ ID NO:50, Ala-Ala-Ser, and SEQ ID NO:54.

Claim 36 (depends on 28)

36. The antibody of claim 28 , wherein the VH domain comprises an amino acid sequence comprising SEQ ID NO:42, SEQ ID NO:44, and SEQ ID NO:46; and the VL domain comprises an amino acid sequence comprising SEQ ID NO:56, SEQ ID NO:58, and SEQ ID NO:60.

Claim 37 (depends on 28)

37. A composition comprising the antibody of claim 28 and a pharmaceutically acceptable excipient, diluent, or carrier.

Claim 38 (depends on 29)

38. A composition comprising the antibody of claim 29 and a pharmaceutically acceptable excipient, diluent, or carrier.

Claim 39 (depends on 30)

39. A composition comprising the antibody of claim 30 and a pharmaceutically acceptable excipient, diluent, or carrier.

Claim 40 (depends on 31)

40. A composition comprising the antibody of claim 31 and a pharmaceutically acceptable excipient, diluent, or carrier.

Claim 41 (depends on 32)

41. A composition comprising the antibody of claim 32 and a pharmaceutically acceptable excipient, diluent, or carrier.

Claim 42 (depends on 35)

42. A composition comprising the antibody of claim 35 and a pharmaceutically acceptable excipient, diluent, or carrier.

Claim 43 (depends on 36)

43. A composition comprising the antibody of claim 36 and a pharmaceutically acceptable excipient, diluent, or carrier.

Claim 45 (depends on 1)

45. The antibody or fragment thereof according to claim 1 , wherein the VH domain further comprises the HCDR1 sequence of SEQ ID NO:36 or 42 and the HCDR2 sequence of SEQ ID NO:38 or 44, and wherein the antibody or fragment thereof further comprises a VL domain that comprises the LCDR1 sequence of SEQ ID NO:50 or 56.

Claim 46 (depends on 1)

46. The antibody or fragment thereof according to claim 1 , wherein the VH domain further comprises the HCDR1 sequence of SEQ ID NO:36 or 42 and the HCDR2 sequence of SEQ ID NO:38 or 44, and wherein the antibody or fragment thereof further comprises a VL domain comprising the LCDR1 sequence of SEQ ID NO:50 or 56 and the LCDR2 sequence of Ala-Ala-Ser or SEQ ID NO:58.

Claim 47 (depends on 44)

47. The antibody or fragment thereof according to claim 44 , wherein the VH domain comprises the amino acid sequence of SEQ ID NO:34.

Claim 48 (depends on 44)

48. The antibody or fragment thereof according to claim 44 , comprising a first and a second copy of the VH domain.

Claim 49 (depends on 44)

49. The antibody or fragment thereof according to claim 44 , wherein the VL domain comprises the amino acid sequence of SEQ ID NO:48.

Claim 50 (depends on 44)

50. The antibody or fragment thereof according to claim 44 , wherein the VL domain comprises the amino acid sequence of SEQ ID NO:48 and the VH domain comprises the amino acid sequence of SEQ ID NO:34.

Claim 51 (depends on 44)

51. The antibody or fragment thereof according to claim 44 , comprising a first and a second copy of the VL domain.

Claim 52 (depends on 44)

52. The antibody or fragment thereof according to claim 44 , comprising a kappa light chain.

Claim 53 (depends on 44)

53. The antibody or fragment thereof according to claim 44 , comprising a constant region.

Claim 54 (depends on 50)

54. The antibody or fragment thereof according to claim 50 , comprising a IgG4-PE constant region of SEQ ID NO: 128.

Claim 55 (depends on 53)

55. The antibody or fragment thereof according to claim 53 , wherein the constant region comprises an IgG4-PE constant region, wherein the IgG4-PE constant region comprises a Leu235Glu mutation and a Ser228Pro mutation relative to the wild-type human IgG4 constant region of SEQ ID NO: 122.

Claim 56 (depends on 44)

56. The antibody or fragment thereof of claim 44 , wherein the VH domain comprises an amino acid sequence comprising SEQ ID NO:36: SEQ ID NO:38: and SEQ ID NO:40; and the VL domain comprises an amino acid sequence comprising SEQ ID NO:50, Ala-Ala-Ser, and SEQ ID NO:54.

Claim 57 (depends on 44)

57. The antibody or fragment thereof of claim 44 , wherein the VH domain comprises an amino acid sequence comprising SEQ ID NO:42, SEQ ID NO:44, and SEQ ID NO:46; and the VL domain comprises an amino acid sequence comprising SEQ ID NO:56, SEQ ID NO:58, and SEQ ID NO:60.

Claim 58 (depends on 56)

58. A composition comprising the antibody or fragment thereof of claim 56 and a pharmaceutically acceptable excipient, diluent, or carrier.

Claim 59 (depends on 57)

59. A composition comprising the antibody or fragment thereof of claim 57 and a pharmaceutically acceptable excipient, diluent, or carrier.

Full Description

No description text available for this patent.

Figures (2)

Fig. 1
Fig. 2

Citations

This patent cites (629)

  • US4663281
  • US4741900
  • US4816397
  • US5219996
  • US5223409
  • US5314995
  • US5403484
  • US5427908
  • US5516637
  • US5545806
  • US5545807
  • US5569825
  • US5571698
  • US5580717
  • US5585089
  • US5625126
  • US5633425
  • US5645835
  • US5658727
  • US5661016
  • US5677425
  • US5698426
  • US5712380
  • US5733743
  • US5750753
  • US5766886
  • US5770429
  • US5780225
  • US5821047
  • US5869046
  • US5869619
  • US5969108
  • US6011003
  • US6028176
  • US6100071
  • US6121022
  • US6331415
  • US6407088
  • US6528055
  • US6528623
  • US6548507
  • US6599906
  • US6803039
  • US6875432
  • US6897294
  • US7029895
  • US7030225
  • US7045615
  • US7056509
  • US7098184
  • US7125551
  • US7129338
  • US7132099
  • US7166283
  • US7196175
  • US7226909
  • US7259247
  • US7261893
  • US7279560
  • US7291331
  • US7300754
  • US7304033
  • US7306800
  • US7368531
  • US7411051
  • US7438905
  • US7456187
  • US7456264
  • US7465445
  • US7482147
  • US7501496
  • US7521541
  • US7572618
  • US7582288
  • US7704500
  • US7722872
  • US7776577
  • US7794710
  • US7812133
  • US7868141
  • US7892540
  • US7932358
  • US7943743
  • US7968689
  • US7972813
  • US7988965
  • US7998478
  • US8008449
  • US8030457
  • US8062640
  • US8080243
  • US8101175
  • US8168179
  • US8168762
  • US8188233
  • US8188234
  • US8318905
  • US8344114
  • US8357371
  • US8389690
  • US8399646
  • US8420098
  • US8426363
  • US8486647
  • US8501184
  • US8530414
  • US8551477
  • US8563698
  • US8598320
  • US8840889
  • US8916155
  • US8956615
  • US8962807
  • US8986694
  • US8992927
  • US9045545
  • US9062105
  • US9067998
  • US9102725
  • US9109034
  • US9139653
  • US9150660
  • US9234043
  • US9376493
  • US9428570
  • US9434785
  • US9512229
  • US9567399
  • US9587030
  • US9617338
  • US9868789
  • US9868790
  • US10118963
  • US10214586
  • US10259880
  • US10604576
  • US10654935
  • US10669342
  • US11396550
  • US2002/0045571
  • US2002/0064555
  • US2002/0081679
  • US2002/0082259
  • US2002/0114814
  • US2002/0150576
  • US2002/0156242
  • US2003/0119038
  • US2003/0124149
  • US2003/0158402
  • US2004/0009553
  • US2004/0023243
  • US2004/0038242
  • US2004/0110226
  • US2004/0191265
  • US2004/0248177
  • US2004/0265309
  • US2005/0085433
  • US2005/0101529
  • US2005/0118625
  • US2005/0147612
  • US2005/0175610
  • US2005/0197285
  • US2005/0260203
  • US2005/0271656
  • US2005/0281822
  • US2005/0281831
  • US2006/0002929
  • US2006/0116508
  • US2006/0147945
  • US2006/0210566
  • US2006/0223088
  • US2006/0223090
  • US2006/0246071
  • US2006/0246483
  • US2007/0015696
  • US2007/0037206
  • US2007/0037748
  • US2007/0041963
  • US2007/0041972
  • US2007/0055056
  • US2007/0082345
  • US2007/0122378
  • US2007/0224663
  • US2007/0292440
  • US2008/0008697
  • US2008/0069795
  • US2008/0103090
  • US2008/0113930
  • US2008/0279862
  • US2009/0053230
  • US2009/0055944
  • US2009/0142352
  • US2009/0232795
  • US2009/0246192
  • US2009/0252749
  • US2009/0269350
  • US2009/0326202
  • US2010/0040610
  • US2010/0040611
  • US2010/0041102
  • US2010/0068194
  • US2010/0068199
  • US2010/0098712
  • US2010/0136028
  • US2010/0150937
  • US2010/0166740
  • US2010/0166768
  • US2010/0183591
  • US2010/0183612
  • US2010/0203056
  • US2010/0233177
  • US2010/0291099
  • US2010/0323359
  • US2011/0027287
  • US2011/0033451
  • US2011/0033465
  • US2011/0065902
  • US2011/0070239
  • US2011/0091481
  • US2011/0105726
  • US2011/0117011
  • US2011/0135662
  • US2011/0142849
  • US2011/0229489
  • US2011/0230392
  • US2011/0256148
  • US2011/0274702
  • US2011/0307966
  • US2012/0014951
  • US2012/0015435
  • US2012/0020975
  • US2012/0020976
  • US2012/0027751
  • US2012/0027765
  • US2012/0058906
  • US2012/0064621
  • US2012/0076799
  • US2012/0077964
  • US2012/0082679
  • US2012/0082680
  • US2012/0185956
  • US2012/0195910
  • US2012/0208208
  • US2012/0208209
  • US2012/0213794
  • US2012/0213797
  • US2012/0219558
  • US2012/0231005
  • US2012/0251544
  • US2012/0269723
  • US2012/0301461
  • US2012/0321879
  • US2012/0328616
  • US2013/0018175
  • US2013/0052201
  • US2013/0058944
  • US2013/0064825
  • US2013/0064834
  • US2013/0071379
  • US2013/0071405
  • US2013/0072665
  • US2013/0079501
  • US2013/0079502
  • US2013/0085265
  • US2013/0085266
  • US2013/0095108
  • US2013/0095109
  • US2013/0115171
  • US2013/0115223
  • US2013/0142783
  • US2013/0183315
  • US2013/0189278
  • US2013/0245235
  • US2013/0273069
  • US2013/0310324
  • US2014/0037648
  • US2014/0044703
  • US2014/0086932
  • US2014/0093497
  • US2014/0161794
  • US2014/0165219
  • US2014/0170157
  • US2014/0286897
  • US2014/0322132
  • US2015/0203580
  • US2015/0239978
  • US2015/0307620
  • US2016/0000909
  • US2016/0002336
  • US2016/0024211
  • US2016/0145344
  • US2016/0215059
  • US2016/0264666
  • US2016/0264675
  • US2016/0304610
  • US2016/0361364
  • US2016/0368997
  • US2017/0002083
  • US2017/0037137
  • US2017/0044250
  • US2017/0260279
  • US2017/0320956
  • US2017/0327586
  • US2017/0327587
  • US2018/0305464
  • US2019/0077867
  • US2019/0275084
  • US2019/0276547
  • US2019/0330351
  • US2020/0231692
  • US2021/0087287
  • US2021/0380699
  • US2021/0395378
  • US2022/0372153
  • US101023102
  • US101248089
  • US101374865
  • US103221427
  • US0438474
  • US0463151
  • US0546073
  • US0984023
  • US1067182
  • US1125585
  • US1158004
  • US0996622
  • US1374901
  • US1502920
  • US1514933
  • US1286668
  • US1618212
  • US2481758
  • US1740617
  • US2650016
  • US2691419
  • US3369745
  • US2812022
  • US3495391
  • US2005-130764
  • US2008-512995
  • US2009-518005
  • US2017-513813
  • US2540490
  • US85/04880
  • USWO 1985/004880
  • USWO 1990/002809
  • USWO 1991/004329
  • USWO 1991/009967
  • USWO 1991/010737
  • USWO 1991/013166
  • USWO 1992/001047
  • USWO 1992/002551
  • USWO 1992/008495
  • USWO 1992/008801
  • USWO 1992/018619
  • USWO 1992/022583
  • USWO 1993/011236
  • USWO 1993/012227
  • USWO 1993/020849
  • USWO 1995/015982
  • USWO 1995/020401
  • USWO 1995/021915
  • USWO 1996/008570
  • USWO 1997/044453
  • USWO 1997/049805
  • USWO 1998/003821
  • USWO 1998/013071
  • USWO 1998/020734
  • USWO 1998/024893
  • USWO 1998/025971
  • USWO 1999/003859
  • USWO 1999/003996
  • USWO 1999/015553
  • USWO 1999/029732
  • USWO 1999/043713
  • USWO 1999/052562
  • USWO 1999/053958
  • USWO 1999/060128
  • USWO 2000/011033
  • USWO 2000/040615
  • USWO 2000/047228
  • USWO 2000/076310
  • USWO 2001/007081
  • USWO 2001/010912
  • USWO 2001/014424
  • USWO 2001/031007
  • USWO 2001/057081
  • USWO 2001/058957
  • USWO 2001/087981
  • USWO 2001/098468
  • USWO 2002/000243
  • USWO 2002/002143
  • USWO 2002/014358
  • USWO 2002/046383
  • USWO 2002/057435
  • USWO 2002/066514
  • USWO 2002/072605
  • USWO 2002/079232
  • USWO 2002/079415
  • USWO 2002/090526
  • USWO 2002/090566
  • USWO 2002/102993
  • USWO 2002/102994
  • USWO 2003/015697
  • USWO 2003/048208
  • USWO 2003/048334
  • USWO 2003/050531
  • USWO 2003/059245
  • USWO 2004/018649
  • USWO 2004/051268
  • USWO 2004/055056
  • USWO 2004/094613
  • USWO 2004/097047
  • USWO 2004/106377
  • USWO 2005/003169
  • USWO 2005/003170
  • USWO 2005/003171
  • USWO 2005/007121
  • USWO 2005/016969
  • USWO 2005/021592
  • USWO 2005/063808
  • USWO 2005/063820
  • USWO 2005/066348
  • USWO 2005/086751
  • USWO 2005/086798
  • US2005/094879
  • USWO 2005/094879
  • USWO 2005/103086
  • USWO 2005/113605
  • USWO 2005/117984
  • US2006/029879
  • US2006/030220
  • USWO 2006/029879
  • USWO 2006/030220
  • USWO 2006/061219
  • USWO 2006/091899
  • USWO 2006/133396
  • USWO 2007/005874
  • USWO 2007/023298
  • USWO 2007/041972
  • USWO 2007/062245
  • USWO 2007/109324
  • USWO 2007/113648
  • US2007/133290
  • USWO 2007/128121
  • USWO 2007/133290
  • USWO 2008/003473
  • USWO 2008/027338
  • USWO 2008/038024
  • USWO 2008/057457
  • USWO 2008/057458
  • USWO 2008/057459
  • USWO 2008/063382
  • USWO 2008/083174
  • USWO 2008/086395
  • USWO 2008/090958
  • USWO 2008/106116
  • USWO 2008/109871
  • USWO 2008/125623
  • USWO 2008/130704
  • USWO 2008/133647
  • USWO 2008/137915
  • USWO 2009/026558
  • USWO 2009/033027
  • USWO 2009/055783
  • USWO 2009/061853
  • USWO 2009/070642
  • USWO 2009/100297
  • USWO 2009/100318
  • USWO 2009/126688
  • USWO 2009/131740
  • USWO 2009/141239
  • USWO 2010/029513
  • USWO 2010/031720
  • USWO 2010/035012
  • USWO 2010/036959
  • USWO 2010/054007
  • USWO 2010/056804
  • USWO 2010/073180
  • USWO 2010/077634
  • USWO 2010/077854
  • USWO 2010/089411
  • USWO 2010/111180
  • USWO 2010/117448
  • USWO 2011/004192
  • USWO 2011/020024
  • USWO 2011/020783
  • USWO 2011/025904
  • USWO 2011/037791
  • USWO 2011/041613
  • USWO 2011/051350
  • USWO 2011/051351
  • USWO 2011/053665
  • USWO 2011/053743
  • USWO 2011/053759
  • USWO 2011/053783
  • USWO 2011/056997
  • US2010/073180
  • USWO 2011/066389
  • USWO 2011/071871
  • USWO 2011/072263
  • USWO 2011/073180
  • USWO 2011/097477
  • USWO 2011/111007
  • USWO 2011/158009
  • USWO 2012/025536
  • USWO 2012/027328
  • USWO 2012/054438
  • USWO 2012/062228
  • USWO 2012/088313
  • USWO 2012/088446
  • USWO 2012/101251
  • USWO 2012/101252
  • USWO 2012/101253
  • USWO 2012/107416
  • USWO 2012/107417
  • USWO 2012/109530
  • USWO 2012/131004
  • USWO 2012/132067
  • USWO 2012/145493
  • USWO 2012/146628
  • USWO 2012/154999
  • USWO 2012/162583
  • USWO 2012/168491
  • USWO 2012/170438
  • USWO 2012/170607
  • USWO 2012/174338
  • USWO 2012/177741
  • USWO 2012/178137
  • US2013/008171
  • USWO 2013/008171
  • USWO 2013/008185
  • USWO 2013/016648
  • USWO 2013/028231
  • USWO 2013/039958
  • USWO 2013/039969
  • USWO 2013/041844
  • USWO 2013/061078
  • USWO 2013/061098
  • USWO 2013/063298
  • USWO 2013/079174
  • USWO 2013/148284
  • USWO 2013/148350
  • USWO 2013/170367
  • USWO 2013/172933
  • USWO 2013/173223
  • USWO 2013/180201
  • USWO 2013/181087
  • USWO 2013/181634
  • USWO 2014/023679
  • USWO 2014/023752
  • USWO 2014/033327
  • USWO 2014/055897
  • USWO 2014/089113
  • USWO 2014/100079
  • USWO 2014/109999
  • USWO 2014/116846
  • USWO 2014/159562
  • USWO 2014/159595
  • USWO 2014/165082
  • USWO 2014/194111
  • USWO 2015/036499
  • USWO 2015/040401
  • USWO 2015/049537
  • USWO 2015/061668
  • USWO 2015/109124
  • USWO 2015/112800
  • USWO 2015/112805
  • USWO 2015/112900
  • USWO 2015/118016
  • USWO 2015/132580
  • USWO 2015/136541
  • USWO 2015/153514
  • USWO 2015/173267
  • USWO 2015/179654
  • USWO 2015/181342
  • USWO 2016/000619
  • USWO 2016/007235
  • USWO 2016/022468
  • USWO 2016/022630
  • USWO 2016/028656
  • USWO 2016/030350
  • USWO 2016/061142
  • USWO 2016/106302
  • USWO 2016/111645
  • USWO 2016/120789
  • USWO 2016/139482
  • USWO 2016/149201
  • USWO 2016/154177
  • USWO 2016/160792
  • USWO 2016/191643
  • USWO 2016/197367
  • USWO 2017/020291
  • USWO 2017/020801
  • USWO 2017/020802
  • USWO 2017/020858
  • USWO 2017/030823
  • USWO 2017/034916
  • USWO 2017/037707
  • USWO 2017/053748
  • USWO 2017/059095
  • USWO 2017/070423
  • USWO 2017/087547
  • USWO 2017/087587
  • USWO 2017/091429
  • USWO 2017/118321
  • USWO 2017/196867
  • USWO 2017/213695
  • USWO 2017/215590
  • USWO 2017/218435
  • USWO 2017/220569
  • USWO 2017/220988
  • USWO 2018/005682
  • USWO 2018/009894
  • USWO 2018/025221
  • USWO 2018/045110
  • USWO 2018/047178
  • USWO 2018/054940
  • USWO 2018/080812
  • USWO 2018/085358
  • USWO 2018/115859
  • USWO 2018/119475
  • USWO 2018/136553
  • USWO 2018/162749
  • USWO 2018/187191
  • USWO 2018/187613
  • USWO 2018/195226
  • USWO 2018/222949
  • USWO 2019/028367